Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results of a Multicenter Phase II Study
-
Published:2001-03-15
Issue:6
Volume:19
Page:1750-1758
-
ISSN:0732-183X
-
Container-title:Journal of Clinical Oncology
-
language:en
-
Short-container-title:JCO
Author:
Schuler Martin1, Herrmann Richard1, De Greve Jacques L.P.1, Stewart A. Keith1, Gatzemeier Ulrich1, Stewart David J.1, Laufman Leslie1, Gralla Richard1, Kuball Jürgen1, Buhl Roland1, Heussel Claus P.1, Kommoss Friedrich1, Perruchoud André P.1, Shepherd Frances A.1, Fritz Mary Ann1, Horowitz Jo Ann1, Huber Christoph1, Rochlitz Christoph1
Affiliation:
1. From the Departments of Medicine III, Radiology, and Pathology, Johannes Gutenberg University, Mainz; Department of Thoracic Oncology, Hospital Grosshansdorf, Grosshansdorf, Germany; Divisions of Oncology and Pneumology, Department of Medicine, Kantonsspital, Basel, Switzerland; Department of Medical Oncology, Oncology Center, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium; Princess Margaret Hospital, University of Toronto, Toronto; Ottawa Regional Cancer Centre, Ottawa, Ontario,...
Abstract
PURPOSE: To study the additional benefit from adenoviral p53 gene therapy in patients undergoing first-line chemotherapy for advanced non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Twenty-five patients with nonresectable NSCLC were enrolled in an open-label, multicenter phase II study of three cycles of regimen A, carboplatin (area under the curve, 6; day 1) plus paclitaxel (175 mg/m2, day 1), or regimen B, cisplatin (100 mg/m2, day 1) plus vinorelbine (25 mg/m2, days 1, 8, 15, and 22) in combination with intratumoral injection of 7.5 × 1012 particles of SCH 58500 (rAd/p53, day 1). Responses of individual tumor lesions were assessed after each cycle, and gene transfer was examined in posttreatment tumor biopsies using reverse transcriptase polymerase chain reaction. RESULTS: There was no difference between the response rate of lesions treated with p53 gene therapy in addition to chemotherapy (52% objective responses) and lesions treated with chemotherapy alone (48% objective responses). Subgroup analysis according to the chemotherapy regimens revealed evidence for increased mean local tumor regressions in response to additional p53 gene therapy in patients receiving regimen B, but not in patients receiving regimen A. There was no survival difference between the two chemotherapy regimens, and the median survival of the cohort was 10.5 months (1-year survival, 44%). Transgene expression was confirmed in tumor samples from 68% of patients, and toxicities attributable to gene therapy were mild to moderate. CONCLUSION: Intratumoral adenoviral p53 gene therapy appears to provide no additional benefit in patients receiving an effective first-line chemotherapy for advanced NSCLC.
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Reference41 articles.
1. Cancer statistics, 1997 2. p53: A Frequent Target for Genetic Abnormalities in Lung Cancer 3. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828,1992-4831, 4. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. 5. Ohsaki Y, Toyshima E, Fujiuchi S, et al: bcl-2 and p53 protein expression in non–small cell lung cancers: Correlation with survival time. Clin Cancer Res 2: 915,1996-920,
Cited by
185 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|